TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04161573

Intervention type: BEHAVIORAL
Intervention: Watching ironic stories
Description: All the participants would be asked to watch a series of self-made stories which are figurative or literal. They have to figure out what is the real meaning of the character's statement. The whole procedure will be done with a computer.

Intervention type: BEHAVIORAL
Intervention: Watching ironic stories
Description: All the participants would be asked to watch a series of self-made stories which are figurative or literal. They have to figure out what is the real meaning of the character's statement. The whole procedure will be done with a computer.
Study: NCT00003311

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin hydrochloride

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate
Study: NCT00003311

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine sulfate
Study: NCT02463968

Intervention type: PROCEDURE
Intervention: Arthrocentesis for synovial fluid draw
Description: Samples will include joint fluid analysis in participants with a knee effusion. Synovial fluid will be drawn via arthrocentesis under sterile conditions. This is a part of standard of care of new new onset joint effusion and is not a novel intervention.
Study: NCT02721550

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Glycididazole
Description: 800mg/m2，dissolved in 100ml physiological saline(Now with chef),ivgtt,finished in 30 minutes,within 60 minutes after intravenous drip for radiation therapy.Three times a week (once every other one day),before radiation therapy, total 4 weeks course.
Study: NCT00732160

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aldosterone infusion (A)
Description: Infusion of exogenous aldosterone (0.7 mcg/kg/hr for 12.5 hrs)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aldosterone infusion (A)
Description: Infusion of exogenous aldosterone (0.7 mcg/kg/hr for 12.5 hrs)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aldosterone infusion (A)
Description: Infusion of exogenous aldosterone (0.7 mcg/kg/hr for 12.5 hrs)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aldosterone infusion (A)
Description: Infusion of exogenous aldosterone (0.7 mcg/kg/hr for 12.5 hrs)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vehicle Infusion (V)
Description: Vehicle infusion for 12.5 hours
Study: NCT01580358

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Shen-Mai San
Description: Shen mai san is composed of three herb medicines, Ginseng radis, Liriope spicata, and Schizandrae fructus and was manufactured into concentrated herbal extract and packed with 0.5g per capsule and labeled by Sun-Ten pharmaceutical company in Taiwan with good manufacturing practice (GMP).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Starch
Description: It was packed in granules with 0.5gm starch. Patients took eight granules three times per day for four weeks.
Study: NCT00732160

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vehicle Infusion (V)
Description: Vehicle infusion for 12.5 hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vehicle Infusion (V)
Description: Vehicle infusion for 12.5 hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vehicle Infusion (V)
Description: Vehicle infusion for 12.5 hours
Study: NCT03145363

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention
Description: The intervention group will receive 2-5 interactive text message sequences per week. These messages will invite students to reply using keywords and short free text replies. Messages come from a library of strength-based peer quotations (reviewed for safety), psychoeducational interactions, and games designed to promote emotional skills and use of resources.
Study: NCT00732160

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High Sodium Diet (HS)
Description: 160 mmol/d sodium diet for 7 days

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High Sodium Diet (HS)
Description: 160 mmol/d sodium diet for 7 days

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High Sodium Diet (HS)
Description: 160 mmol/d sodium diet for 7 days

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High Sodium Diet (HS)
Description: 160 mmol/d sodium diet for 7 days

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low Sodium Diet (LS)
Description: 20 mmol/d sodium diet for 9 days

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low Sodium Diet (LS)
Description: 20 mmol/d sodium diet for 9 days

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low Sodium Diet (LS)
Description: 20 mmol/d sodium diet for 9 days
Study: NCT03145363

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: The control group will receive 1-2 (non-interactive) text messages per week containing general SoS concepts (e.g., Remember: more strengths are better when times get tough).
Study: NCT02256072

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Plan Your Lifespan Website
Description: Participants in the intervention arm will navigate the advance planning tool, Plan Your Lifespan, a Web-based planning tool that provides information for seniors related to advanced health planning for home services in specific content areas of: hospitalizations, falls, Alzheimer's, dementia, as well as communicating with others. A minimum of 15 minutes and a maximum of 45 minutes will be allotted for navigating this website.The Plan Your Lifespan website is also interactive in that it allows participants to enter their information and share it with others to facilitate conversations and decision-making.

Intervention type: OTHER
Group type: OTHER
Intervention: Go4Life Website
Description: Participants in the attention control arm will navigate an electronic educational session via a National Institute on Aging at NIH Website, Go4Life, a website about physical activity and exercise as it is a topic of interest to seniors. A minimum of 15 minutes and a maximum of 45 minutes will be allotted for navigating the website. The website is interactive and comparable to the intervention tool: http://go4life.nia.nih.gov/get-started).
Study: NCT04384497

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 convalescent plasma
Description: Treatment with convalescent plasma (200ml, up to a maximum of 7 CP infusions). Plasma from consenting individuals who have recovered from SARS-CoV-2 infection.
Study: NCT01610401

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: metformin 500 mg three times a day, for 3 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pretreatment with metformin in combination of infusion of caffeine.
Description: Pretreatment with metformin 500 mg three times a day for 3 days, in combination with pretreatment with caffeine (4 mg/kg intravenously over 10 minutes) prior to FMD measurement

Intervention type: DRUG
Group type: OTHER
Intervention: No pretreatment with metformin in combination with infusion of caffeine
Description: No pretreatment with metformin in combination with pretreatment with caffeine (4 mg/kg intravenously over 10 minutes).
Study: NCT02795962

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Direct transfer to an Endovascular Center
Description: Cluster randomized controlled study: allocation to active or no intervention arm will be performed accordingly to a pre-established temporal sequence
Study: NCT02648269

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SEL-110

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SEL-212

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SEL-212

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SEL-037
Study: NCT04206007

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: UMC119-06
Description: Cohort 1: Low does of UMC119-06 Cohort 2: Medium does of UMC119- 06 Cohort 3: High does of UMC119-06
Study: NCT01297920

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brinzolamide 1%/brimonidine tartrate 0.2% ophthalmic suspension

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Brinzolamide ophthalmic suspension, 1%

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Brimonidine tartrate ophthalmic solution, 0.2%
Study: NCT05548673

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychoeducation
Description: The implementation phase is planned for Ankara Yıldırım Beyazıt University (AYBU) Nursing Faculty students. The stress management training program, which consists of eight sessions, is completed in 8 weeks, once a week.
Study: NCT02940080

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary
Study: NCT03678883

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 9-ING-41
Description: Starting dose of-9-ING-41 will be administered on Day 1 and 4 each week of a 21-day cycle. 9-ING-41 will be administered intravenously over 60 minutes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 9-ING-41
Description: Starting dose of-9-ING-41 will be administered on Day 1 and 4 each week of a 21-day cycle. 9-ING-41 will be administered intravenously over 60 minutes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 9-ING-41
Description: Starting dose of-9-ING-41 will be administered on Day 1 and 4 each week of a 21-day cycle. 9-ING-41 will be administered intravenously over 60 minutes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 9-ING-41
Description: Starting dose of-9-ING-41 will be administered on Day 1 and 4 each week of a 21-day cycle. 9-ING-41 will be administered intravenously over 60 minutes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 9-ING-41
Description: Starting dose of-9-ING-41 will be administered on Day 1 and 4 each week of a 21-day cycle. 9-ING-41 will be administered intravenously over 60 minutes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 9-ING-41
Description: Starting dose of-9-ING-41 will be administered on Day 1 and 4 each week of a 21-day cycle. 9-ING-41 will be administered intravenously over 60 minutes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 9-ING-41
Description: Starting dose of-9-ING-41 will be administered on Day 1 and 4 each week of a 21-day cycle. 9-ING-41 will be administered intravenously over 60 minutes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 9-ING-41
Description: Starting dose of-9-ING-41 will be administered on Day 1 and 4 each week of a 21-day cycle. 9-ING-41 will be administered intravenously over 60 minutes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine - 21 day cycle
Description: Gemcitabine 1250 mg/m2 as a 30-minute intravenous infusion on Days 1 and 8 of a 21-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin.
Description: Doxorubicin 75 mg/m2, intravenous bolus on Day 1 of a 21-day cycle up to a maximum lifetime dose of 550 mg/m2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lomustine
Description: Lomustine 30 mg/m² orally as a single dose, weekly for twelve weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin.
Description: Carboplatin AUC 6 IV over 1 hour on Day 1 of a 21-day cycle.
Study: NCT01631903

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: telepristone acetate 12 mg
Description: 12 mg, vaginal capsule, once daily for 4 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: telepristone acetate 3 mg
Description: 3 mg, vaginal capsule, once daily for 3 months
Study: NCT03678883

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin.
Description: Carboplatin AUC 6 IV over 1 hour on Day 1 of a 21-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab paclitaxel.
Description: Nab-paclitaxel 125 mg/m2 intravenously on Days 1, 8 and 15 of a 28-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel.
Description: Paclitaxel 175 mg/m2 intravenously over 3 hours on Day 1 of a 21-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine - 28 day cycle
Description: Gemcitabine 1000 mg/m2 intravenously over 30-minutes on Days 1, 8 and 15 of a 28-day cycle
Study: NCT00732160

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low Sodium Diet (LS)
Description: 20 mmol/d sodium diet for 9 days
Study: NCT01007019

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YH4808 30mg
Description: YH4808 30mg (single dose)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YH4808 50mg
Description: YH4808 50mg (single dose)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YH4808 100mg
Description: YH4808 100mg (single dose)
Study: NCT03678883

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Irinotecan 350 mg/m2 intravenously over 90-minutes on Day 1 of a 21-day cycle
Study: NCT04252365

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab
Description: Given i.v.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pembrolizumab
Description: Given i.v.
Study: NCT01007019

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YH4808 200mg
Description: YH4808 200mg (single dose)
Study: NCT02507973

Intervention type: OTHER
Intervention: Airway Pressure Release Ventilation
Description: Airway pressure release ventilation (APRV) is a mode of mechanical ventilation that switches between high (PHigh) and low (PLow) continuous positive airway pressure while allowing spontaneous breathing at both phases. Alveolar recruitment and oxygenation occur during PHigh whereas ventilation occurs during brief releases to PLow.

Intervention type: OTHER
Intervention: Low Tidal Volume Ventilation
Description: After enrollment and collection of baseline Intracranial pressure and hemodynamic status for 30 minutes the participants will undergo low tidal volume mechanical ventilation (LOTV), serving as a control mode of ventilation. LOTV is most commonly used for trauma patients with lung injury. LOTV provides oxygen in smaller amounts, without overstretching the lungs
Study: NCT03239158

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cancer ablation
Description: Tumors bigger than 2 cm are fit for ablation therapy, percutaneously under CT scan or ultrasound.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cancer ablation
Description: Tumors bigger than 2 cm are fit for ablation therapy, percutaneously under CT scan or ultrasound.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Life information rehabilitation therapy
Description: Each treatment: one bottle solution each day, consecutive 3 months, oral administration

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Life information rehabilitation therapy
Description: Each treatment: one bottle solution each day, consecutive 3 months, oral administration
Study: NCT03714308

Intervention type: DRUG
Intervention: Ivt. Aflibercept (Eylea, BAY86-5321)
Description: Treatment is applied according to routine clinical practice and independent of the study setting.

Intervention type: DRUG
Intervention: Ivt. Aflibercept (Eylea, BAY86-5321)
Description: Treatment is applied according to routine clinical practice and independent of the study setting.

Intervention type: DRUG
Intervention: Ivt. Aflibercept (Eylea, BAY86-5321)
Description: Treatment is applied according to routine clinical practice and independent of the study setting.
Study: NCT02519465

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 10l/min
Description: For inhalation was used diethilene penta-acetic triamine technetium (99mTc-DTPA) with radioactivity of 1 millicuries (Noble et al., 2007) and 0.9% saline solution with a total volume of 1 ml using vibrating mesh inhaler (Aerogen Ltd, Galway , Ireland) with the respiratory care system for the high flow ( Fisher \& Paykel healthcare, New Zealand) and nasal cannula (Fisher \& Paykel healthcare, New Zealand) with flow 10l/min

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 10l/min
Description: For inhalation was used diethilene penta-acetic triamine technetium (99mTc-DTPA) with radioactivity of 1 millicuries (Noble et al., 2007) and 0.9% saline solution with a total volume of 1 ml using vibrating mesh inhaler (Aerogen Ltd, Galway , Ireland) with the respiratory care system for the high flow ( Fisher \& Paykel healthcare, New Zealand) and nasal cannula (Fisher \& Paykel healthcare, New Zealand) with flow 10l/min

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 30l/min
Description: For inhalation was used diethilene penta-acetic triamine technetium (99mTc-DTPA) with radioactivity of 1 millicuries (Noble et al., 2007) and 0.9% saline solution with a total volume of 1 ml using vibrating mesh inhaler (Aerogen Ltd, Galway , Ireland) with the respiratory care system for the high flow ( Fisher \& Paykel healthcare, New Zealand) and nasal cannula (Fisher \& Paykel healthcare, New Zealand) with flow 30l/min.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 30l/min
Description: For inhalation was used diethilene penta-acetic triamine technetium (99mTc-DTPA) with radioactivity of 1 millicuries (Noble et al., 2007) and 0.9% saline solution with a total volume of 1 ml using vibrating mesh inhaler (Aerogen Ltd, Galway , Ireland) with the respiratory care system for the high flow ( Fisher \& Paykel healthcare, New Zealand) and nasal cannula (Fisher \& Paykel healthcare, New Zealand) with flow 30l/min.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 50l/min
Description: For inhalation was used diethilene penta-acetic triamine technetium (99mTc-DTPA) with radioactivity of 1 millicuries (Noble et al., 2007) and 0.9% saline solution with a total volume of 1 ml using vibrating mesh inhaler (Aerogen Ltd, Galway , Ireland) with the respiratory care system for the high flow ( Fisher \& Paykel healthcare, New Zealand) and nasal cannula (Fisher \& Paykel healthcare, New Zealand) with flow 50l/min.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 50l/min
Description: For inhalation was used diethilene penta-acetic triamine technetium (99mTc-DTPA) with radioactivity of 1 millicuries (Noble et al., 2007) and 0.9% saline solution with a total volume of 1 ml using vibrating mesh inhaler (Aerogen Ltd, Galway , Ireland) with the respiratory care system for the high flow ( Fisher \& Paykel healthcare, New Zealand) and nasal cannula (Fisher \& Paykel healthcare, New Zealand) with flow 50l/min.
Study: NCT01761864

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: academic detailing intervention
Study: NCT01514331

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: SIMV+VG mode of ventilation (synchronized intermittent mandatory ventilation+volume guarantee)
Description: Neonates who need mechanical ventilation will be ventilated with SIMV+VG mode

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: PSV+VG (pressure support ventilation+volume guarantee)
Description: Neonates who need mechanical ventilation will be ventilated with PSV+VG
Study: NCT02850354

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: anti-g maneuvers
Description: investigate the effects of anti-g maneuvers on cardiovascular and respiratory tolerance to the push-pull-effect.
Study: NCT01007019

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YH4808
Description: YH4808 400mg (single dose)
Study: NCT02608203

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [68Ga]-DOTANOC PET/CT
Study: NCT00469651

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MSP 3 Long Synthetic Peptide
Description: Lyophilized MSP3 vaccine adjuvanted in Aluminium hydroxide

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MSP3 vaccine
Description: Lyophilized vaccine adjuvanted in Aluminium hydroxide

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Hepatitis B vaccine
Description: Hepatitis B vaccine adjuvanted in Aluminium hydroxide
Study: NCT01631903

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: telepristone acetate 6 mg
Description: 6 mg, vaginal capsule, once daily for 3 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: telepristone acetate 12 mg
Description: 12 mg, vaginal capsule, once daily, for 3 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: telepristone acetate 24 mg
Description: 24 mg, vaginal capsule, once daily for 4 months
Study: NCT01355068

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epanutin Infatabs (Phenytoin)
Description: Chewable Tablet, 50 mg, Single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dilantin Infatabs (Phenytoin)
Description: Chewable Tablet, 50 mg, Single dose
Study: NCT03207022

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: axillary brachial plexus block
Description: ultrasound guided axillary brachial plexus block with 20 ml local anaesthetic lidocaine with epinephrine and clonidine

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: axillary brachial plexus block
Description: ultrasound guided axillary brachial plexus block with 20 ml local anaesthetic lidocaine with epinephrine and clonidine
Study: NCT04969016

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: LSA (liquid skin adhesive)
Description: surgical wound closure with liquid skin adhesive (LiquiBand®)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: stapler
Description: surgical wound closure with stapler
Study: NCT02236546

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: [18F]fluorodeoxyglucose
Description: FDG is administered intravenously approximately 60 minutes prior to the start of PET image acquisition.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Molecular assays on biopsied tissue
Description: Correlative studies

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: positron emission tomography
Description: Undergo FDG-PET/CT

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: computed tomography
Description: CT that is part of FDG-PET/CT is a low-milliampere, low-resolution scan that is used for anatomic localization and attenuation correction for PET images.
Study: NCT03778177

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: transcranial electrical brain stimulation
Description: Pain ratings will be recorded before and after transcranial brain electrical stimulation procedures using a Visual Analog Scale (VAS).
Study: NCT04212494

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Thrombus aspiration
Description: Percutaneous Coronary Intervention with manual aspiration thrombectomy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PCI Alone
Description: Percutaneous Coronary Intervention without manual aspiration thrombectomy
Study: NCT04032470

Intervention type: DEVICE
Intervention: Deep Brain Stimulation Systems (DBS)
Description: Subjects receiving DBS implant for treatment of Essential Tremor